5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
Adverse O
reactions O
, O
sometimes O
severe O
and O
life-threatening O
or O
fatal O
, O
have O
been O
seen O
in O
clinical O
trials O
with O
ZALTRAP O
, O
including O
: O
* O
Fistula O
Formation O
: O
Discontinue O
ZALTRAP O
if O
fistula O
occurs O
. O

( O
2.2 O
, O
5.4 O
) O
* O
Hypertension O
: O
Monitor O
blood O
pressure O
and O
treat O
hypertension O
. O

Temporarily O
suspend O
ZALTRAP O
if O
hypertension O
is O
not O
controlled O
. O

Discontinue O
ZALTRAP O
if O
hypertensive O
crisis O
develops O
. O

( O
2.2 O
, O
5.5 O
) O
* O
Arterial O
Thromboembolic O
Events O
( O
ATE O
) O
( O
e.g. O
, O
transient O
ischemic O
attacks O
, O
cerebrovascular O
accident O
, O
angina O
pectoris O
) O
: O
Discontinue O
ZALTRAP O
if O
ATE O
develops O
. O

( O
5.6 O
) O
* O
Proteinuria O
: O
Monitor O
urine O
protein O
. O

Suspend O
ZALTRAP O
when O
proteinuria O
> O
= O
2 O
grams O
per O
24 O
hours O
. O

Discontinue O
ZALTRAP O
if O
nephrotic O
syndrome O
or O
thrombotic O
microangiopathy O
( O
TMA O
) O
develops O
. O

( O
2.2 O
, O
5.7 O
) O
* O
Neutropenia O
and O
Neutropenic O
Complications O
: O
Delay O
administration O
of O
ZALTRAP/FOLFIRI O
until O
neutrophil O
count O
is O
> O
= O
1.5 O
* O
10 O
9 O
/L O
. O

( O
5.8 O
) O
* O
Diarrhea O
and O
Dehydration O
: O
Incidence O
of O
severe O
diarrhea O
and O
dehydration O
is O
increased O
. O

Monitor O
elderly O
patients O
more O
closely O
. O

( O
5.9 O
, O
8.5 O
) O
* O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
: O
Discontinue O
ZALTRAP O
. O

( O
5.10 O
) O
5.1 O
Hemorrhage O
Patients O
treated O
with O
ZALTRAP O
have O
an O
increased O
risk O
of O
hemorrhage B-OSE_Labeled_AE
, O
including O
severe O
and O
sometimes O
fatal B-NonOSE_AE
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
bleeding B-OSE_Labeled_AE
/ O
hemorrhage B-OSE_Labeled_AE
( O
all O
grades O
) O
were O
reported O
in O
38 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
19 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
hemorrhagic B-OSE_Labeled_AE
events I-OSE_Labeled_AE
, O
including O
gastrointestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
and O
post B-OSE_Labeled_AE
- I-OSE_Labeled_AE
procedural I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
were O
reported O
in O
3 O
% O
of O
patients O
receiving O
ZALTRAP/FOLFIRI O
compared O
with O
1 O
% O
of O
patients O
receiving O
placebo/FOLFIRI O
. O

Severe O
intracranial B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
and O
pulmonary B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
/ O
hemoptysis B-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
events O
have O
also O
occurred O
in O
patients O
receiving O
ZALTRAP O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
bleeding B-NonOSE_AE
. O

Do O
not O
initiate O
ZALTRAP O
in O
patients O
with O
severe O
hemorrhage B-Not_AE_Candidate
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
develop O
severe O
hemorrhage B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.2 O
Gastrointestinal O
Perforation O
Gastrointestinal B-OSE_Labeled_AE
( I-OSE_Labeled_AE
GI I-OSE_Labeled_AE
) I-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
including O
fatal B-NonOSE_AE
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
can O
occur O
in O
patients O
receiving O
ZALTRAP O
. O

Across O
three O
Phase O
3 O
placebo-controlled O
clinical O
studies O
( O
colorectal B-Not_AE_Candidate
, O
pancreatic O
, O
and O
lung O
cancer I-Not_AE_Candidate
populations O
) O
, O
the O
incidence O
of O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
( O
all O
grades O
) O
was O
0.8 O
% O
for O
patients O
treated O
with O
ZALTRAP O
and O
0.3 O
% O
for O
patients O
treated O
with O
placebo O
. O

Grade O
3-4 O
GI B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
events O
occurred O
in O
0.8 O
% O
of O
patients O
treated O
with O
ZALTRAP O
and O
0.2 O
% O
of O
patients O
treated O
with O
placebo O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
GI B-NonOSE_AE
perforation I-NonOSE_AE
. O

Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
experience O
GI B-NonOSE_AE
perforation I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.3 O
Compromised O
Wound O
Healing O
ZALTRAP O
impairs B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
in O
animal O
models O
[ O
see O
Nonclinical O
Toxicology O
( O
13.2 O
) O
] O
. O

Grade O
3 O
compromised B-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
was O
reported O
in O
2 O
patients O
( O
0.3 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
and O
in O
none O
of O
the O
patients O
treated O
with O
placebo/FOLFIRI O
regimen O
. O

Suspend O
ZALTRAP O
for O
at O
least O
4 O
weeks O
prior O
to O
elective O
surgery O
. O

Do O
not O
resume O
ZALTRAP O
for O
at O
least O
4 O
weeks O
following O
major O
surgery O
and O
until O
the O
surgical O
wound O
is O
fully O
healed O
. O

For O
minor O
surgery O
such O
as O
central O
venous O
access O
port O
placement O
, O
biopsy O
, O
and O
tooth O
extraction O
, O
ZALTRAP O
may O
be O
initiated/resumed O
once O
the O
surgical O
wound O
is O
fully O
healed O
. O

Discontinue O
ZALTRAP O
in O
patients O
with O
compromised B-NonOSE_AE
wound I-NonOSE_AE
healing I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.4 O
Fistula O
Formation O
Fistula B-OSE_Labeled_AE
formation I-OSE_Labeled_AE
involving O
gastrointestinal I-OSE_Labeled_AE
and O
non-gastrointestinal O
sites O
occurs O
at O
a O
higher O
incidence O
in O
patients O
treated O
with O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
fistulas B-OSE_Labeled_AE
( I-OSE_Labeled_AE
anal I-OSE_Labeled_AE
, O
enterovesical O
, O
enterocutaneous O
, O
colovaginal O
, O
intestinal O
sites O
) O
were O
reported O
in O
9 O
of O
611 O
patients O
( O
1.5 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
regimen O
and O
3 O
of O
605 O
patients O
( O
0.5 O
% O
) O
treated O
with O
placebo/FOLFIRI O
regimen O
. O

Grade O
3 O
GI B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
formation O
occurred O
in O
2 O
patients O
treated O
with O
ZALTRAP O
( O
0.3 O
% O
) O
and O
in O
1 O
placebo-treated O
patient O
( O
0.2 O
% O
) O
. O

Discontinue O
ZALTRAP O
therapy O
in O
patients O
who O
develop O
fistula B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.5 O
Hypertension O
ZALTRAP O
increases O
the O
risk O
of O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
. O

There O
is O
no O
clinical O
trial O
experience O
administering O
ZALTRAP O
to O
patients O
with O
NYHA B-Not_AE_Candidate
class I-Not_AE_Candidate
III I-Not_AE_Candidate
or I-Not_AE_Candidate
IV I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3 O
hypertension B-OSE_Labeled_AE
( O
defined O
as O
requiring O
adjustment O
in O
existing O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
or O
treatment O
with O
more O
than O
one O
drug O
) O
was O
reported O
in O
1.5 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
and O
19 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
. O

Grade O
4 O
hypertension B-OSE_Labeled_AE
( O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
) O
was O
reported O
in O
1 O
patient O
( O
0.2 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
. O

Among O
those O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
developing O
Grade O
3-4 O
hypertension B-OSE_Labeled_AE
, O
54 O
% O
had O
onset O
during O
the O
first O
two O
cycles O
of O
treatment O
. O

Monitor O
blood O
pressure O
every O
two O
weeks O
or O
more O
frequently O
as O
clinically O
indicated O
during O
treatment O
with O
ZALTRAP O
. O

Treat O
with O
appropriate O
anti B-NonOSE_AE
- I-NonOSE_AE
hypertensive I-NonOSE_AE
therapy I-NonOSE_AE
and O
continue O
monitoring O
blood O
pressure O
regularly O
. O

Temporarily O
suspend O
ZALTRAP O
in O
patients O
with O
uncontrolled B-NonOSE_AE
hypertension I-NonOSE_AE
until O
controlled O
, O
and O
permanently O
reduce O
ZALTRAP O
dose O
to O
2 O
mg O
per O
kg O
for O
subsequent O
cycles O
. O

Discontinue O
ZALTRAP O
in O
patients O
with O
hypertensive B-NonOSE_AE
crisis I-NonOSE_AE
or O
hypertensive B-NonOSE_AE
encephalopathy I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.6 O
Arterial O
Thromboembolic O
Events O
Arterial B-OSE_Labeled_AE
thromboembolic I-OSE_Labeled_AE
events I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ATE I-OSE_Labeled_AE
) O
, O
including O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
and O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
occurred O
more O
frequently O
in O
patients O
who O
have O
received O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
ATE B-OSE_Labeled_AE
was O
reported O
in O
2.6 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
1.7 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
events O
occurred O
in O
11 O
patients O
( O
1.8 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
and O
4 O
patients O
( O
0.7 O
% O
) O
treated O
with O
placebo/FOLFIRI O
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
experience O
an O
ATE B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.7 O
Proteinuria O
Severe O
proteinuria B-OSE_Labeled_AE
, O
nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
and O
thrombotic B-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TMA I-OSE_Labeled_AE
) O
occurred O
more O
frequently O
in O
patients O
treated O
with O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
proteinuria B-OSE_Labeled_AE
was O
reported O
in O
62 O
% O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
41 O
% O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
proteinuria B-OSE_Labeled_AE
occurred O
in O
8 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
to O
1 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Nephrotic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
occurred O
in O
2 O
patients O
( O
0.5 O
% O
) O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
none O
of O
the O
patients O
treated O
with O
placebo/FOLFIRI O
. O

TMA B-OSE_Labeled_AE
was O
reported O
in O
3 O
of O
2258 O
patients O
with O
cancer B-Not_AE_Candidate
enrolled O
across O
completed O
studies O
. O

Monitor O
proteinuria B-NonOSE_AE
by O
urine O
dipstick O
analysis O
and/or O
urinary O
protein O
creatinine O
ratio O
( O
UPCR O
) O
for O
the O
development O
or O
worsening O
of O
proteinuria B-NonOSE_AE
during O
ZALTRAP O
therapy O
. O

Patients O
with O
a O
dipstick O
of O
> O
=2+ O
for O
protein O
or O
a O
UPCR O
greater O
than O
1 O
should O
undergo O
a O
24-hour O
urine O
collection O
. O

Suspend O
ZALTRAP O
administration O
for O
proteinuria B-NonOSE_AE
2 O
grams O
per O
24 O
hours O
or O
more O
, O
and O
resume O
when O
proteinuria B-NonOSE_AE
is O
less O
than O
2 O
grams O
per O
24 O
hours O
. O

If O
recurrent O
, O
suspend O
until O
proteinuria B-NonOSE_AE
is O
less O
than O
2 O
grams O
per O
24 O
hours O
and O
then O
permanently O
reduce O
the O
ZALTRAP O
dose O
to O
2 O
mg O
per O
kg O
. O

Discontinue O
ZALTRAP O
in O
patients O
who O
develop O
nephrotic B-NonOSE_AE
syndrome I-NonOSE_AE
or O
TMA B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

5.8 O
Neutropenia O
and O
Neutropenic O
Complications O
A O
higher O
incidence O
of O
neutropenic B-OSE_Labeled_AE
complications I-OSE_Labeled_AE
( O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
and O
neutropenic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
) O
occurred O
in O
patients O
receiving O
ZALTRAP O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3-4 O
neutropenia B-OSE_Labeled_AE
occurred O
in O
37 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
30 O
% O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

Grade O
3-4 O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
occurred O
in O
4 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
2 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
neutropenic B-OSE_Labeled_AE
infection I-OSE_Labeled_AE
/sepsis O
occurred O
in O
1.5 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
and O
1.2 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Monitor O
CBC O
with O
differential O
count O
at O
baseline O
and O
prior O
to O
initiation O
of O
each O
cycle O
of O
ZALTRAP O
. O

Delay O
ZALTRAP/FOLFIRI O
until O
neutrophil O
count O
is O
at O
or O
above O
1.5 O
* O
10 O
9 O
/L O
. O

5.9 O
Diarrhea O
and O
Dehydration O
The O
incidence O
of O
severe O
diarrhea B-OSE_Labeled_AE
is O
increased O
in O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
. O

In O
patients O
with O
mCRC B-Not_AE_Candidate
, O
Grade O
3-4 O
diarrhea B-OSE_Labeled_AE
was O
reported O
in O
19 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
8 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
. O

Grade O
3-4 O
dehydration B-OSE_Labeled_AE
was O
reported O
in O
4 O
% O
of O
patients O
treated O
with O
ZALTRAP/FOLFIRI O
compared O
to O
1 O
% O
of O
patients O
treated O
with O
placebo/FOLFIRI O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
) O
] O
. O

The O
incidence O
of O
diarrhea B-NonOSE_AE
is O
increased O
in O
patients O
who O
are O
age O
65 O
years O
or O
older O
as O
compared O
to O
patients O
younger O
than O
65 O
years O
of O
age O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Monitor O
elderly O
patients O
closely O
for O
diarrhea B-NonOSE_AE
. O

5.10 O
Reversible O
Posterior O
Leukoencephalopathy O
Syndrome O
( O
RPLS O
) O
RPLS B-OSE_Labeled_AE
( O
also O
known O
as O
posterior B-OSE_Labeled_AE
reversible I-OSE_Labeled_AE
encephalopathy I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
) O
was O
reported O
in O
0.5 O
% O
of O
3795 O
patients O
treated O
with O
ZALTRAP O
monotherapy O
or O
in O
combination O
with O
chemotherapy O
. O

Confirm O
the O
diagnosis O
of O
RPLS B-NonOSE_AE
with O
MRI O
and O
discontinue O
ZALTRAP O
in O
patients O
who O
develop O
RPLS B-NonOSE_AE
. O

Symptoms O
usually O
resolve O
or O
improve O
within O
days O
, O
although O
some O
patients O
have O
experienced O
ongoing O
neurologic B-NonOSE_AE
sequelae I-NonOSE_AE
or O
death B-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.2 O
) O
] O
. O

